EUVIMEDEUVIMED entdecken
Vergleichsstudie

TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis

Nhan Hien Phan, Ho Jong Chun, Jung Suk Oh, Su Ho Kim, Byung Gil Choi

Abdominal Radiology · 25.09.2024 · 50 (3) · 1198-1208

DOI: 10.1007/s00261-024-04573-5 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Abdominal Radiology, online erschienen am 25.09.2024. Verfasst von Nhan Hien Phan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Liver Neoplasms, Embolization, Therapeutic. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study aimed to compare transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) as first-line treatments for unresectable HCC > 8 cm. METHODS: This retrospective study analyzed 129 HCC patients with tumor diameters greater than 8 cm from January 2010 to December 2021, including 40 patients who received TARE, and 89 patients treated with TACE as primary treatment. Following Propensity Score Matching (PSM), 40 patients from each group were harmonized for baseline characteristics. Tumor responses were evaluated using mRECIST criteria, and survival outcomes were compared between treatment groups using Kaplan-Meier curves and the Log-rank test. RESULTS: There was no significant difference in the objective response rate (ORR) and disease control rate (DCR) at 3, 6, and 12 months between the two groups; ORR and DCR were 72.6%, 83.1% in TACE group vs. 72.5%. 87.5% in TARE group for best tumor response (p-values: 0.625 and 0.981, respectively). Overall survival (OS) and progression-free survival (PFS) between the two groups were comparable pre- and post-PSM. After PSM, the OS was 33.2 months (20.0-58.6) in TACE group and 38.1 months (13.8-98.1) in TARE group (p = 0.53), while PFS was 11.5 months (7.7-18.4) and 9.1 months (5.2-23.8) respectively. After PSM, post-embolization syndrome developed more in TACE group (100% vs. 75%, p = 0.002). Major adverse events were 72% in TACE group vs. 5% in TARE group (p < 0.001). CONCLUSIONS: TARE and TACE offer comparable efficacy in managing large HCC, with TARE providing a safer profile, suggesting its consideration as a preferable initial therapeutic approach for unresectable HCC patients with tumors larger than 8 cm.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularChemoembolization, TherapeuticLiver NeoplasmsEmbolization, TherapeuticHumansPropensity ScoreFemaleMaleRetrospective StudiesMiddle AgedAgedTreatment Outcome

Stichwörter der Autor:innen

Large hepatocellular carcinomaRadioembolizationTransarterial chemoembolization

Autor:innen und Institutionen

  • Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Radiology Centre, Hanoi Medical University Hospital, Hanoi Medical University, Hanoi, Vietnam.
  • Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. hojongchun@gmail.com.

Zitieren

APA

Phan, N. H., Chun, H. J., Oh, J. S., Kim, S. H., & Choi, B. G. (2024). TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis. Abdominal Radiology, 50(3), 1198-1208. https://doi.org/10.1007/s00261-024-04573-5

Vancouver

Phan NH, Chun HJ, Oh JS, Kim SH, Choi BG. TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis. Abdominal Radiology. 2024;50(3):1198-1208. doi:10.1007/s00261-024-04573-5

BibTeX
@article{Phan2024,
  author = {Phan, Nhan Hien and Chun, Ho Jong and Oh, Jung Suk and Kim, Su Ho and Choi, Byung Gil},
  title = {TACE vs. TARE for HCC ≥ 8 cm: A propensity score analysis},
  journal = {Abdominal Radiology},
  year = {2024},
  volume = {50},
  number = {3},
  pages = {1198--1208},
  doi = {10.1007/s00261-024-04573-5}
}
Kostenlos starten →